BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 32949719)

  • 21. Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors.
    Gómez-Ganau S; Castillo J; Cervantes A; de Julián-Ortiz JV; Gozalbes R
    Curr Top Med Chem; 2020; 20(18):1628-1639. PubMed ID: 32493189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, Synthesis, Molecular Docking, and Biological Evaluation of Isatin-Based Fused Heterocycles As Epidermal Growth Factor Receptor Inhibitors.
    Kumar A; Kumar B; Bhatia R
    Assay Drug Dev Technol; 2023 Jul; 21(5):222-233. PubMed ID: 37439798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies.
    Aiebchun T; Mahalapbutr P; Auepattanapong A; Khaikate O; Seetaha S; Tabtimmai L; Kuhakarn C; Choowongkomon K; Rungrotmongkol T
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33921332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
    Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel 4-arylaminoquinazolines bearing
    Zhang Y; Chen L; Li X; Gao L; Hao Y; Li B; Yan Y
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1668-1677. PubMed ID: 31530043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, Synthesis,
    Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
    Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
    Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
    Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A New Series of Indeno[1,2-
    Özdemir A; Ciftci H; Sever B; Tateishi H; Otsuka M; Fujita M; Altıntop MD
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.
    Greve G; Schiffmann I; Pfeifer D; Pantic M; Schüler J; Lübbert M
    BMC Cancer; 2015 Dec; 15():947. PubMed ID: 26675484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents.
    Minnelli C; Laudadio E; Mobbili G; Galeazzi R
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32138321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
    Milligan SA; Burke P; Coleman DT; Bigelow RL; Steffan JJ; Carroll JL; Williams BJ; Cardelli JA
    Clin Cancer Res; 2009 Aug; 15(15):4885-94. PubMed ID: 19638461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
    Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
    J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers.
    El-Sharief AMS; Ammar YA; Belal A; El-Sharief MAMS; Mohamed YA; Mehany ABM; Elhag Ali GAM; Ragab A
    Bioorg Chem; 2019 Apr; 85():399-412. PubMed ID: 30665034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and cytotoxicity of chimeric erlotinib-alkylphospholipid hybrids.
    Alam MM; Hassan AHE; Lee KW; Cho MC; Yang JS; Song J; Min KH; Hong J; Kim DH; Lee YS
    Bioorg Chem; 2019 Mar; 84():51-62. PubMed ID: 30481646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and
    Le Y; Gan Y; Fu Y; Liu J; Li W; Zou X; Zhou Z; Wang Z; Ouyang G; Yan L
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):555-564. PubMed ID: 31967481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.
    Mowafy S; Farag NA; Abouzid KA
    Eur J Med Chem; 2013 Mar; 61():132-45. PubMed ID: 23142066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.